文献速递临床试验与 GCP基础与转化研究

奥氮平治疗创伤性脑损伤后激越:随机对照试验研究方案

Use of olanzapine to treat agitation in traumatic brain injury: study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-07-20

BACKGROUND: Agitation is common in the early stages of recovery from traumatic brain injury (TBI), when patients are in post-traumatic amnesia (PTA). Agitation is associated with risk of harm to patients and caregivers.…

要点

  • 在PTA期TBI患者中,奥氮平联合环境管理对比安慰剂联合环境管理,评估激越改善。
  • 主要疗效指标为PTA期间激越行为量表平均分,奥氮平起始5 mg/日,最大20 mg/日。
  • 结局涵盖出院时及出院后3个月功能、认知、医疗服务利用与成本效果。

核心结论

  • 该试验旨在提供证据,判断奥氮平在推荐环境管理之上能否减少TBI后PTA期激越,并评估安全性、成本效果及长期功能影响。

研究设计与样本

  • 干预组接受奥氮平,对照组接受安慰剂,疗程持续至PTA结束;所有参与者均接受针对激越的最佳环境管理。

主要发现

  • 原文未报告试验结果;方案设定主要疗效通过PTA期间激越行为量表平均分的组间比较评估。

关键数值与推荐

  • 奥氮平起始剂量5 mg/日,可递增至最大20 mg/日。
  • 治疗期间每日测量激越与PTA,每周监测不良事件;PTA结束后继续监测激越2周。
  • 出院时评估激越水平与功能健康,出院后3个月测量功能结局与医疗服务利用。

临床怎么用

  • 若试验证实有效且安全,可为TBI后PTA期激越在环境管理基础上加用奥氮平提供循证依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Agitation is common in the early stages of recovery from traumatic brain injury (TBI), when patients are in post-traumatic amnesia (PTA). Agitation is associated with risk of harm to patients and caregivers. Recent guidelines recommend that agitation during PTA is managed using environmental modifications. Agitation is also frequently treated pharmacologically, with the use of atypical antipsychotics such as olanzapine among the most common. This is despite a lack of well-designed studies to support the use of antipsychotics within this context. This study will be a double-blind, placebo-controlled randomised controlled trial. We will examine the efficacy, safety, cost-effectiveness and outcomes associated with the use of olanzapine for reducing agitation in patients in PTA following TBI over and above recommended environmental management. METHODS: Fifty-eight TBI rehabilitation inpatients who are in PTA and are agitated will receive olanzapine or placebo for the duration of PTA. All participants will additionally receive optimal environmental management for agitation. Measures of agitation, PTA and health will be undertaken at baseline. Treatment administration will begin at a dose of 5 mg daily and may be escalated to a maximum dose of 20 mg per day. Throughout the treatment period, agitation and PTA will be measured daily, and adverse events monitored weekly. Efficacy will be assessed by treatment group comparison of average Agitated Behaviour Scale scores during PTA. Participants will cease treatment upon emergence from PTA. Agitation levels will continue to be monitored for a further 2 weeks, post-treatment measures of health will be undertaken and cognitive and functional status will be assessed. Level of agitation and functional health will be assessed at hospital discharge. At 3 months post-discharge, functional outcomes and health service utilisation will be measured. DISCUSSION: This trial will provide crucial evidence to inform the management of agitation in patients in PTA following TBI. It will provide guidance as to whether olanzapine reduces agitation over and above recommended environmental management or conversely whether it increases or prolongs agitation and PTA, increases length of inpatient hospitalisation and impacts longer term cognitive and functional outcomes. It will also speak to the safety and cost-effectiveness of olanzapine use in this population. TRIAL REGISTRATION: ANZCTR ACTRN12619000284167 . Registered on 25 February 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Phyland RK, McKay A, Olver J, et al. Use of olanzapine to treat agitation in traumatic brain injury: study protocol for a randomised controlled trial. Trials. 2020. PMID: 32690072. doi:10.1186/s13063-020-04553-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。